Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study
Standard
Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. / Waldeyer, Christoph; Seiffert, Moritz; Staebe, Nils; Braetz, Julian; Kohsiack, Rebecca; Ojeda, Francisco; Schofer, Niklas; Karakas, Mahir; Zeller, Tanja; Sinning, Christoph; Schrage, Benedikt; Westermann, Dirk; Sydow, Karsten; Blankenberg, Stefan; Brunner, Fabian J; Schnabel, Renate B.
in: CLIN THER, Jahrgang 39, Nr. 11, 11.2017, S. 2311-2320.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study
AU - Waldeyer, Christoph
AU - Seiffert, Moritz
AU - Staebe, Nils
AU - Braetz, Julian
AU - Kohsiack, Rebecca
AU - Ojeda, Francisco
AU - Schofer, Niklas
AU - Karakas, Mahir
AU - Zeller, Tanja
AU - Sinning, Christoph
AU - Schrage, Benedikt
AU - Westermann, Dirk
AU - Sydow, Karsten
AU - Blankenberg, Stefan
AU - Brunner, Fabian J
AU - Schnabel, Renate B
N1 - Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.
PY - 2017/11
Y1 - 2017/11
N2 - PURPOSE: Although the efficacy of lipid-lowering medication (LLM) in patients with coronary artery disease (CAD) is well established, the majority of patients fail to achieve their LDL-C goals. The evidence for measurement of LDL-C to achieve these goals is limited. The goal of the present study, therefore, was to analyze ambulatory LLM management in relation to performance of LDL-C measurements and achieved LDL-C levels after the initial diagnosis of CAD.METHODS: The study followed up a subcohort of 200 patients with newly diagnosed CAD of the INTERCATH trial, an observational study including patients undergoing coronary angiography. In addition to baseline information, data were collected on LLM, performance of lipid measurements, and laboratory results at a minimum of 6 months' postdischarge.FINDINGS: The mean age of the sample was 67.9 years, and 36.0% were women. In 34.5% of all patients, no measurement of LDL-C levels was performed during follow-up. We found no differences in baseline characteristics between patients with and without LDL-C measurements during follow-up. In patients with measurement of LDL-C levels, the frequency of intensification of statin medication according to LDL-C reduction was higher compared with those patients without LDL-C measurement (23.6% vs 4.3%; P < 0.001); all other categories of intensity adjustment were comparable. In patients with 3 LDL-C measurements, achieved LDL-C levels were significantly lower (mean, 81 mg/dL), and a higher proportion reached an LDL-C level <70 mg/dL (44.7%) compared with patients with 1 (95 mg/dL [P = 0.013]; 21.8%) or 2 (91 mg/dL [P = 0.037]; 28.9%) LDL-C measurements despite comparable LDL-C levels at baseline. Ezetimibe was used in 3.5% of the entire study cohort.IMPLICATIONS: We found no differences in patient characteristics between patients with and without LDL-C measurements after being newly diagnosed with CAD. Performance and frequency of LDL-C measurements were clearly associated with better, higher frequency of intensification of statin medication, lower achieved LDL-C levels, and a higher proportion of patients achieving the LDL-C goal of <70 mg/dL. These results suggest an important role of LDL-C measurements for secondary prevention after the initial diagnosis of CAD.
AB - PURPOSE: Although the efficacy of lipid-lowering medication (LLM) in patients with coronary artery disease (CAD) is well established, the majority of patients fail to achieve their LDL-C goals. The evidence for measurement of LDL-C to achieve these goals is limited. The goal of the present study, therefore, was to analyze ambulatory LLM management in relation to performance of LDL-C measurements and achieved LDL-C levels after the initial diagnosis of CAD.METHODS: The study followed up a subcohort of 200 patients with newly diagnosed CAD of the INTERCATH trial, an observational study including patients undergoing coronary angiography. In addition to baseline information, data were collected on LLM, performance of lipid measurements, and laboratory results at a minimum of 6 months' postdischarge.FINDINGS: The mean age of the sample was 67.9 years, and 36.0% were women. In 34.5% of all patients, no measurement of LDL-C levels was performed during follow-up. We found no differences in baseline characteristics between patients with and without LDL-C measurements during follow-up. In patients with measurement of LDL-C levels, the frequency of intensification of statin medication according to LDL-C reduction was higher compared with those patients without LDL-C measurement (23.6% vs 4.3%; P < 0.001); all other categories of intensity adjustment were comparable. In patients with 3 LDL-C measurements, achieved LDL-C levels were significantly lower (mean, 81 mg/dL), and a higher proportion reached an LDL-C level <70 mg/dL (44.7%) compared with patients with 1 (95 mg/dL [P = 0.013]; 21.8%) or 2 (91 mg/dL [P = 0.037]; 28.9%) LDL-C measurements despite comparable LDL-C levels at baseline. Ezetimibe was used in 3.5% of the entire study cohort.IMPLICATIONS: We found no differences in patient characteristics between patients with and without LDL-C measurements after being newly diagnosed with CAD. Performance and frequency of LDL-C measurements were clearly associated with better, higher frequency of intensification of statin medication, lower achieved LDL-C levels, and a higher proportion of patients achieving the LDL-C goal of <70 mg/dL. These results suggest an important role of LDL-C measurements for secondary prevention after the initial diagnosis of CAD.
KW - Aged
KW - Anticholesteremic Agents/therapeutic use
KW - Cholesterol, LDL/blood
KW - Cohort Studies
KW - Coronary Artery Disease/drug therapy
KW - Ezetimibe/therapeutic use
KW - Female
KW - Humans
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Lipids/blood
KW - Male
KW - Middle Aged
KW - Secondary Prevention/methods
U2 - 10.1016/j.clinthera.2017.10.005
DO - 10.1016/j.clinthera.2017.10.005
M3 - SCORING: Journal article
C2 - 29103665
VL - 39
SP - 2311
EP - 2320
JO - CLIN THER
JF - CLIN THER
SN - 0149-2918
IS - 11
ER -